Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: Benefit due to influenza and pneumococcal vaccination not demonstrated

被引:27
作者
Skull, Susan A.
Andrews, Ross M.
Byrnes, Graham B.
Kelly, Heath A.
Nolan, Terence M.
Brown, Graham V.
Campbell, Donald A.
机构
[1] Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Parkville, Vic 3052, Australia
[2] Menzies Sch Hlth Res, Casuarina, NT, Australia
[3] Univ Melbourne, Sch Populat Hlth, Ctr Mol Environm Genet & Anal Epidemiol, Melbourne, Vic 3010, Australia
[4] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia
[5] Univ Melbourne, Sch Populat Hlth, Melbourne, Vic 3010, Australia
[6] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3050, Australia
[7] Monash Univ, Inst Hlth Serv Res, Monash Med Ctr, Clayton, Vic 3168, Australia
基金
英国医学研究理事会;
关键词
influenza vaccines; pneumococcal vaccines; pneumonia;
D O I
10.1016/j.vaccine.2007.03.015
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Benefits from influenza and 23-valent pneumococcal polysaccharide (23vPPV) vaccines against invasive pneumococcal disease and laboratory confirmed influenza have been well documented. However, their effectiveness against pneumonia remains controversial for community-based elderly >= 65 years. Using a case-cohort design we examined incremental VE of 23vPPV over and above influenza vaccine against hospitalization with community-acquired pneumonia (HCAP) in two large Australian hospitals. 1952 cases (ICD-10-AM codes for pneumonia: J10-J18) and 2927 randomly selected cohort subjects were studied. Vaccination status was confirmed by providers. Benefit against HCAP was not demonstrated in multivariate analysis for influenza vaccine compared with neither vaccine (RR 1.02, 95%CI 0.84-1.20) or for both vaccines compared with influenza vaccine (RR 0.98, 95%CI 0.81-1.18). The current program of funding these vaccines for the elderly is not having a discernable impact on HCAP in this setting. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4631 / 4640
页数:10
相关论文
共 56 条
[1]   Assessment of vaccine coverage following the introduction of a publicly funded pneumococcal vaccine program for the elderly in Victoria, Australia [J].
Andrews, RM .
VACCINE, 2005, 23 (21) :2756-2761
[2]  
[Anonymous], MODERN EPIDEMIOLOGY
[3]  
[Anonymous], 1998, Modern Epidemiology
[4]  
[Anonymous], COCHRANE DATABASE SY
[5]   Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and non-invasive pneumococcal infection in elderly people: a large-scale retrospective cohort study [J].
Ansaldi, F ;
Turello, V ;
Bastone, G ;
De Luca, S ;
Rosselli, R ;
Durando, P ;
Sticchi, L ;
Gasparini, R ;
Delfino, E ;
Icardi, G .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2005, 33 (05) :490-500
[6]  
Assendelft WJJ, 2004, NETH J MED, V62, P36
[7]  
Austrian R, 1976, Trans Assoc Am Physicians, V89, P184
[8]   Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older:: a prospective study [J].
Christenson, B ;
Lundbergh, P ;
Hedlund, J ;
Örtqvist, Å .
LANCET, 2001, 357 (9261) :1008-1011
[9]   EVALUATING VACCINATION EFFECTIVENESS AND VACCINE EFFICACY BY MEANS OF CASE-CONTROL STUDIES [J].
COMSTOCK, GW .
EPIDEMIOLOGIC REVIEWS, 1994, 16 (01) :77-89
[10]   Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain:: A case-control study [J].
Domínguez, A ;
Salleras, L ;
Fedson, DS ;
Izquierdo, C ;
Ruíz, L ;
Ciruela, P ;
Fenoll, A ;
Casal, J .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (09) :1250-1257